Seite an seite to these efforts is the recently completed SHIVA trial, which compared clinical outcomes between patients receiving targeted brokers, selected based on panel sequencing, and those given conventional chemotherapy, in patients with any type of metastatic solid tumor refractory to standard treatment [21]

Seite an seite to these efforts is the recently completed SHIVA trial, which compared clinical outcomes between patients receiving targeted brokers, selected based on panel sequencing, and those given conventional chemotherapy, in patients with any type of metastatic solid tumor refractory to standard treatment [21]. actionable genomic alterations within individual tumors [7]. Rapid advances in genomic technologies have fueled translational cancer research, providing opportunities intended for acquisition of precision genomic information to help guide clinical management of cancer patients. Concomitant with decreasing costs, the advancement of genomic technologies has placed clinicians and researchers in a unique position to translate genomic results to the clinic. The first assays to screen cancer patients intended for somatic alterations targetable by drugs were based on detection of single gene alterations [8]. For example , early studies investigating the genomic landscapes of breast cancers identifiedHER2copy number amplifications in ~30% of patients, noting that overexpression ofHER2was associated with poor prognosis [9]. Trastuzumab was among the first monoclonal antibody-based targeted drugs developed, targetingHER2-expressing tumor cells. The success of clinical trials investigating the use of trastuzumab in the treatment ofHER2-positive breast cancers has resulted in routine screening forHER2amplifications in the management of breast cancer patients [10]. Another early example of a successful single-gene assay is that of chronic myeloid leukemia (CML), in which the BCRABL fusion protein results from a chromosomal translocation event found in ~90% of CML patients [11]. Imatinib, a tyrosine kinase inhibitor developed in the late 1990s, exhibited significant antitumor effects in cells harboring theBCRABLfusion [12]. Screening intended for the presence ofBCRABLfusion transcripts thus became routine in the use of imatinib for CML patients [13]. Continued discovery of recurrent driver alterations in different cancers, concomitant with further development of targeted drugs, eventually generated an impetus intended for the construction of multiplexed assays to detect multiple genomic alterations in cancer patients. Extending from single-gene-based assays, panel sequencing offered the opportunity to discover genomic alterations in tumors that were not known to harbor Phenylbutazone (Butazolidin, Butatron) such alterations. Early applications of multi-gene assays aimed at guiding cancer treatment focused on a small number of genes directly associated with targeted brokers, including examples such as a panel capable of detecting 41 alterations in 9 genes relevant in lung cancer [14], as well as a panel used to detect 120 mutations in 13 genes relevant across a broad spectrum of tumor types [15]. Advancements in genomic technology have since led to development of panels encompassing as many as 4, 000 alterations across 143 genes [16], and incorporation of panel methods has become routine in several cancer control organizations such as the BC Cancer Agency [17] and Memorial Sloan Kettering Cancer Center [18]. Investigations into the feasibility and efficacy of applying panel sequencing techniques to large populations of patients with advanced cancer are ongoing Phenylbutazone (Butazolidin, Butatron) and include trials such as NCI-MATCH (Molecular Analysis for Phenylbutazone (Butazolidin, Butatron) Therapy Choice) [19], TAPUR (Targeted Agent and Profiling Utilization Registry) [20], and TOP (The Oncopanel Pilot; clinicaltrials. gov/show/NCT02171286). Parallel TSPAN4 to these efforts is the recently completed SHIVA trial, which compared clinical outcomes between patients receiving targeted brokers, selected based on panel sequencing, and those given conventional chemotherapy, in patients with any type of metastatic solid tumor refractory to standard treatment [21]. Results of SHIVA showed no or limited improvement in progression-free survival for patients receiving targeted therapy [22]. However , it remains unclear whether these results from the SHIVA study can be attributed to an inability of panel sequencing to guide effective therapy rather than other factors, such as the selection of genes included in the panel or a restricted selection of targeted agents.